<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01800214</url>
  </required_header>
  <id_info>
    <org_study_id>CIHR MOP-13129</org_study_id>
    <secondary_id>MOP-13129</secondary_id>
    <nct_id>NCT01800214</nct_id>
  </id_info>
  <brief_title>The Sunnybrook Dementia Study</brief_title>
  <acronym>SDS</acronym>
  <official_title>Prospective Neuroimaging, Cognition and Behavioural Study of Alzheimer's, Vascular, Parkinson's, Frontotemporal and Mixed Dementias</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sunnybrook Health Sciences Centre</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Sunnybrook Research Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Waterloo</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Baycrest</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Sunnybrook Health Sciences Centre</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The prospect of disease-modifying therapies in the pipeline for Alzheimer's Disease (AD) has&#xD;
      intensified efforts to use brain imaging more effectively for diagnosis and monitoring of&#xD;
      dementing illnesses. There is also emerging awareness of the destructive interplay between AD&#xD;
      and Cerebrovascular Disease (CVD) in our aging population; both disorders share common&#xD;
      vascular risk factors and may respond to similar prevention treatments. Brain mapping&#xD;
      techniques capitalize on the fact that different neurodegenerative diseases target particular&#xD;
      brain areas. Brain shrinkage and stroke disease can be quantified on Magnetic Resonance&#xD;
      Imaging (MRI) using computerized analysis.&#xD;
&#xD;
      This ongoing study applies advanced MR imaging analysis, genetic testing and standardized&#xD;
      cognitive and functional assessments done at yearly intervals to measure and monitor&#xD;
      longitudinal change in patients with AD, vascular and other neurodegenerative diseases and&#xD;
      potentially to measure modifying effects of emerging therapies. Over 1300 patients (Mild&#xD;
      Cognitive Impairment or dementia from AD, Vascular, Frontotemporal or Lewy Body Disease) and&#xD;
      140 normal elderly have already been enrolled, with 180 autopsies.&#xD;
&#xD;
      This study utilizes specialized imaging analysis software packages to reliably quantify brain&#xD;
      tissue volumes and small vessel disease, the most common type of CVD.&#xD;
&#xD;
      The SDS also investigates other potential biomarkers of dementia such as eye-tracking,&#xD;
      optical coherence tomography, gait and balance, and the gut microbiome to explore their&#xD;
      clinical utility.&#xD;
&#xD;
      Results from this study will help to improve diagnosis, to customize treatment, and to better&#xD;
      monitor disease-modifying therapies currently under investigation should they become&#xD;
      applicable to everyday practice.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 1995</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2025</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Ecologic or Community</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Volumetric change in brain structures and brain lesions on Magnetic Resonance Imaging (MRI) across the dementias covarying for age, sex, education and Apolipoprotein E (ApoE) status</measure>
    <time_frame>5 years</time_frame>
    <description>Brain structures including whole brain, hippocampus, tissue volumes and cortical thickness in predefined regions of interest; brain lesions including lacunes, subcortical white matter hyperintensities, and stroke</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical decline as measured by detailed conventional neuropsychological testing, instrumental and standard activities of daily living assessments, caregiver forms, and behavioral psychiatric inventories</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of change in perfusion patterns measured on Single Photon Emission Computerized Tomography (SPECT) at baseline and followup contrasts on a voxel-wise basis using Statistical Parametric Mapping (SPM), or in 79 predefined regions of interest</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Group differences for each cognitive, imaging and biomarker measurement</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinico-pathologic correlations between autopsy-confirmed histopathology and clinical features including clincial diagnosis, regaional atrophy, regional hypoperfusion, and white matter interintensities on MRI</measure>
    <time_frame>5 years</time_frame>
  </secondary_outcome>
  <number_of_groups>8</number_of_groups>
  <enrollment type="Anticipated">1300</enrollment>
  <condition>Dementia</condition>
  <arm_group>
    <arm_group_label>Alzheimer's disease (AD)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Vascular Cognitive Disorders (VCD)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Lewy Body Disease (LBD)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Frontotemporal Dementia (FTD)</arm_group_label>
    <description>Behavioral-variant Frontotemporal Dementia (bvFTD) Language-variant Frontoemporal Dementia including Semantic dementia (SD) and Progressive non-fluent aphasia (PNFA) Corticobasal degeneration (CBD) Progressive supranuclear palsy (PSP)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mild Cognitive Impairment (MCI)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Cognitively Normal (CN)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Small Vessel Disease -Neurodegenerative (SVD)</arm_group_label>
  </arm_group>
  <arm_group>
    <arm_group_label>Subjective Cognitive Complaints (SCC)</arm_group_label>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood&#xD;
&#xD;
      Retention: Samples with microbiome&#xD;
&#xD;
      Description:&#xD;
&#xD;
      Fecal Sample&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The study population consisted of a sample of outpatients who attended a tertiary-care&#xD;
        neurology clinic at the Sunnybrook Health Sciences Centre.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Patient Inclusion Criteria (General):&#xD;
&#xD;
          -  Age between 40 and 90 (inclusive)&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Completed 8 years of education or higher&#xD;
&#xD;
          -  Visual and auditory acuity adequate for neuropsychological testing&#xD;
&#xD;
          -  Mini-Mental State Exam (MMSE) score â‰¥ 16&#xD;
&#xD;
        Patient Exclusion Criteria (General):&#xD;
&#xD;
          -  Possible secondary causes of dementia, concomitant or history of neurological or&#xD;
             psychiatric illness (other than stroke or Parkinsonism)&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past 2 years&#xD;
&#xD;
        Normal Control Inclusion Criteria:&#xD;
&#xD;
          -  Age between 40-90&#xD;
&#xD;
          -  Fluent in English&#xD;
&#xD;
          -  Completed 8 years of education or higher&#xD;
&#xD;
          -  No significant memory complaints&#xD;
&#xD;
        Normal Control Exclusion Criteria:&#xD;
&#xD;
          -  Being treated or history of being treated for psychiatric or neurological illness&#xD;
&#xD;
          -  History of alcohol or substance abuse or dependence within the past 2 years&#xD;
&#xD;
          -  Current use of psychoactive medications (e.g. antidepressant, neuroleptics, chronic&#xD;
             anxiolytics or sedative hypnotics, etc.)&#xD;
&#xD;
          -  Medical contraindications to MRI&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sandra E Black, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Sunnybrook Health Sciences Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Morgan Koo, BScH.</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>83757</phone_ext>
    <email>morgan.koo@sunnybrook.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Christopher Scott, MSc.</last_name>
    <phone>416-480-6100</phone>
    <phone_ext>83792</phone_ext>
    <email>christopher.scott@sunnybrook.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sunnybrook Health Sciences Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://sunnybrook.ca/research/content/?page=sri_groups_cogneuro_focus</url>
    <description>Study Info</description>
  </link>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 25, 2013</study_first_submitted>
  <study_first_submitted_qc>February 25, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 27, 2013</study_first_posted>
  <last_update_submitted>March 19, 2021</last_update_submitted>
  <last_update_submitted_qc>March 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sunnybrook Health Sciences Centre</investigator_affiliation>
    <investigator_full_name>Dr. Sandra E Black</investigator_full_name>
    <investigator_title>Brill Chair in Neurology</investigator_title>
  </responsible_party>
  <keyword>neurodengeneration</keyword>
  <keyword>neuroimaging</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dementia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

